This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
KUALA LUMPUR (Aug 9): The FBM KLCI rose 0.26% at the midday break today and stayed firmly above the 1,800-point level, tracking gains at regional markets.
HLFBF 7251 BATS 4162 2089 7077 5029 5347 1201 5225 TNABY 2836 IHHHF PNAGF 5183 PECGF UPBMF 1082 7765 6033 2593 PNADF TNABF Q0F 3719
KUALA LUMPUR (Aug 9): The FBM KLCI managed to hold its position above the 1,800-point level at mid-morning today, but gains were seen capped in line with the subdued regional markets.
HLFBF 7172 5198 1082 7412 7043 7077 2852 5029 5347 5225 1201 3301 TNABY 5819 2836 TNABF Q0F IHHHF 3719
KUALA LUMPUR (Aug 7): The FBM KLCI rose 0.43% at the midday break today as index-linked blue chip stocks lifted the local benchmark index.
HLFBF 7062 7052 7060 7036 1082 5681 BATS 4162 5014 6033 4634 1783 5029 PNADF 5347 5016 1589 SGPBY TNABY 2739 MYPRY TNABF PNAGF
2018-08-07 theedgemarkets - 1
KUALA LUMPUR (Aug 7): The FBM KLCI rose 0.29% in early trade this morning, tracking the steady regional markets, lifted by select index-linked blue chips.
HLFBF 7172 1082 BATS 4162 5246 3034 6033 KLKBY 2445 PNADF 5819 PNAGF 3719
KUALA LUMPUR (Aug 6): The FBM KLCI slid 0.34 point or 0.02% after China's proposed retaliatory tariffs on US goods hit Asian shares. At 5pm, the KLCI closed at 1,779.75 points after volatile trade as investors evaluated the latest turn of events concerning the China-US trade war.
HLFBF UPBMF 1082 2089
KUALA LUMPUR (Aug 6): The FBM KLCI retreated at the midday break today, weighed by select blue chips as the local index showed some indications of a short-term consolidation.
HLFBF UPBMF 1082 7113 TPGVF 2089 9334 6033 TGLVY 0143 KLKBY 5139 2445 PNADF 5225 3301 0037 0900 Q0F IHHHF PNAGF 1929
KUALA LUMPUR (Aug 3): The FBM KLCI clawed into positive territory at the midday break today, lifted by gains at Tenaga Nasional Bhd and other select blue chips.
HLFBF 7172 2089 5014 0020 2852 KLKBY 5347 3867 TNABY MYTEF PNAGF UPBMF 1082 7765 6033 5139 2445 PNADF 4863 6645 0900 5819 MYPRY TNABF
KUALA LUMPUR (Aug 3): The FBM KLCI retreated at mid-morning today, dragged by losses at Telekom Malaysia Bhd (TM) and other select blue chips, against the backdrop of a set of tentative regional markets.
HLFBF UPBMF 1082 7113 5681 TPGVF 5015 2089 0020 TGLVY 4863 3867 0126 5517 5819 MYTEF 2836
KUALA LUMPUR (Aug 1): The FBM KLCI reversed its earlier loss and climbed into positive territory at the midday break today, tracking gains at the regional markets.
HLFBF 7036 7374 5134 GMALY 2852 5029 5347 0035 4715 TNABY 5208 PNAGF 1929 GMALF 1082 ORHLF 6033 7123 5436 4006 PNADF 0026 5819 TNABF
KUALA LUMPUR (Aug 1): The FBM KLCI dipped 0.27% in early trade today on some mild profit taking against the backdrop of higher regional markets, dragged by losses including at Tenaga Nasional Bhd and Genting Bhd.
HLFBF 5249 5347 TNABY UPBMF 1082 TNABF 5246 2089 GEBHF
KUALA LUMPUR (July 31): The FBM KLCI closed 13.99 points or 0.79% higher at its intraday high after investors bought KLCI-linked stocks including Tenaga Nasional Bhd and Hong Leong Financial Group Bhd. At 5pm, the KLCI settled at 1,784.25 points.
HLFBF 5347 TNABY 1082 TNABF BSMAF 1818
KUALA LUMPUR (July 31): The FBM KLCI reversed its earlier losses at the midday break today, lifted by select index-linked blue chips, but the broader market sentiment remained tepid, tracking regional markets.
7083 HLFBF 1082 5032 NFLX BATS 4162 3794 9334 6033 7277 2852 PNADF 5225 3301 3867 4723 Q0F IHHHF 6807 PNAGF 1929
KUALA LUMPUR (July 30): The FBM KLCI remained subdued at the midday break today, tracking its regional peers.
HLFBF APEXF 7090 8621 7036 BATS 4162 5014 5029 3026 5225 3867 1589 2739 IHHHF PNAGF 1082 5681 6033 5139 PNADF 0900 MYPRY Q0F 3719
KUALA LUMPUR (July 26): The FBM KLCI appeared to take a breather from its recent uptrend today, but not entirely perturbed by news of the offer by the entire Khazanah Nasional Bhd board to resign this morning.
HLFBF 9385 FB 1082 7113 5681 TPGVF 5031 BATS 4162 5246 9334 6033 TGLVY 5139 PNADF 5347 3301 0900 TNABY TNABF PNAGF 3719
10h - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
11h - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
11h - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET